首页 / 院系成果 / 成果详情页

Refractory Indolent Non-Hodgkin Lymphoma 期刊论文 会议论文

编号：

3197964a-cccb-4c37-8847-f0c3730724d0
作者：

Gribben, J.^[1] Trneny, M.^[2] Izutsu, K.^[3] Fowler, N. H.^[4] Hong, X.^[5] Zhu, J.^[6] Zhang, H.^[7] Offner, F.^[8] Scheliga, A.^[9] Nowakowski, G.^[10] Pinto, A.^[11] Re, F.^[12] Fogliatto, L. M.^[13] Scheinberg, P.^[14] Flinn, I.^[15] Moreira, C.^[16] Liu, D.^[17] Kalambakas, S.^[17] Fustier, P.^[18] Wu, C.^[17] Leonard, J. P.^[19,20,21]
语种：

英文
期刊：

BRITISH JOURNAL OF HAEMATOLOGY ISSN：0007-1048 2019 年 185 卷 (79 - 79) ; MAR
收录：
关键词：

follicular lymphoma indolent lymphoma lenalidomide marginal zone lymphoma NHL rituximab
推荐引用方式
GB/T 7714：

Gribben J.,Trneny M.,Izutsu K., et al. Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma [J].BRITISH JOURNAL OF HAEMATOLOGY,2019,185:79-79.
APA：

Gribben J.,Trneny M.,Izutsu K.,Fowler N. H.,&Leonard J. P..(2019).Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma .BRITISH JOURNAL OF HAEMATOLOGY,185:79-79.
MLA：

Gribben J., et al. "Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma" .BRITISH JOURNAL OF HAEMATOLOGY 185(2019):79-79.

浏览次数：7  下载次数：0

浏览次数：7

下载次数：0

打印次数：0

Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma 期刊论文会议论文